The trial, sponsored by the Icahn School of Medicine at Mount Sinai, investigates Riluzole's efficacy in treating mild Alzheimer's disease, a significant unmet medical need given the increasing prevalence of cognitive aging disorders. The study's completion and the use of established biomarkers (FDG-PET and MRS) enhance its credibility and potential for future commercialization. If successful, Riluzole could position itself as a novel therapeutic option in a market dominated by acetylcholinesterase inhibitors and other symptomatic treatments. The competitive landscape includes ongoing research into disease-modifying therapies, which may impact market entry strategies and pricing. Diligence should focus on the trial's results and the potential for further studies to validate findings and secure regulatory approval.